Stock CYTK CYTOKINETICS, INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
52.79 USD +0.98% Intraday chart for Cytokinetics, Incorporated +8.82% -36.77%
Jun. 07 Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing MT
Jun. 05 Sector Update: Health Care Stocks Advance Late Afternoon MT

Evolution of the average Target Price on Cytokinetics, Incorporated

Price target over the last 5 years

History of analyst recommendation changes

b349321cd1e3c916346.MhtFOHhkXlCjGfbMH2qYkmYqRCQEgAr-D6SeCF_BadI.e28PdhpdFjjvScH-RQnw2QREd2pv6FqRZNDyTTH1WIJgQwQKLShpIZs0rw~9b5fff402f27b19d8995dba32cf0c0af

Analyst Recommendations on Cytokinetics, Incorporated

Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing MT
B. Riley Cuts Price Target on Cytokinetics to $92 From $122, Maintains Buy Rating MT
Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing MT
Truist Securities Lowers Price Target on Cytokinetics to $70 From $86, Maintains Buy Rating MT
JMP Securities Adjusts Cytokinetics Price Target to $78 From $106, Maintains Market Outperform Rating MT
Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating MT
Needham Adjusts Price Target on Cytokinetics to $72 From $108, Maintains Buy Rating MT
Cytokinetics Plans $500 Million Common Stock Offering -- Shares Drop After Hours MT
Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating MT
Cytokinetics Insider Sold Shares Worth $1,012,265, According to a Recent SEC Filing MT
Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing MT
Mizuho Securities Adjusts Price Target on Cytokinetics to $99 From $103, Maintains Buy Rating MT
UBS Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $92 From $61 MT
Mizuho Securities Boosts Price Target on Cytokinetics to $103 From $80, Keeps Buy Rating MT
B. Riley Raises Cytokinetics' PT to $122 From $66, Keeps Buy Rating; Notes Heightened Conviction in Aficamten Taking Dominant Market Share Cardiac Myosin Inhibitor Market MT
Truist Securities Raises Cytokinetics' Price Target to $86 From $60, Buy Rating Kept MT
Needham Raises Cytokinetics' Price Target to $108 From $60, Keeps Buy Rating MT
HC Wainwright Raises Cytokinetics Price Target to $94 From $58, Maintains Buy Rating MT
Cantor Fitzgerald Raises Cytokinetics Price Target to $101 From $65, Maintains Overweight Rating MT
Goldman Sachs Starts Coverage on Cytokinetics with Buy Rating, $50 Price Target MT
B. Riley Initiates Cytokinetics With Buy Rating, $66 PT; Says Aficamten's Differentiation Remains Underappreciated MT
UBS Trims Cytokinetics' Price Target to $61 From $62, Keeps Buy Rating MT
HC Wainwright Adjusts Cytokinetics Price Target to $58 From $49, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Cytokinetics' Price Target to $65 From $59, Keeps Overweight Rating MT
SVB Initiates Cytokinetics at Outperform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
52.79 USD
Average target price
83.35 USD
Spread / Average Target
+57.90%
High Price Target
107 USD
Spread / Highest target
+102.69%
Low Price Target
60 USD
Spread / Lowest Target
+13.66%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cytokinetics, Incorporated

B. Riley
Truist Securities
JMP Securities
Raymond James
Needham & Co.
Oppenheimer
Mizuho Securities
UBS
Cantor Fitzgerald
HC Wainwright
Goldman Sachs
SVB Securities LLC
JPMorgan Chase
BofA Securities
Morgan Stanley
Piper Sandler
Jefferies & Co.
Barclays
Wolfe Research

Ratings for Cytokinetics, Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CYTK Stock
  4. Consensus Cytokinetics, Incorporated